CORD-19:e847d433e7424152a9846673209cb73027415ecd / 98290-98392 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/e847d433e7424152a9846673209cb73027415ecd","sourcedb":"CORD-19","sourceid":"e847d433e7424152a9846673209cb73027415ecd","text":"*Tigecycline susceptibility defined according to FDA package insert (Tygacil Ò, 2005) where available.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T983","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T72604","span":{"begin":0,"end":102},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T983","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T72604","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T28","span":{"begin":0,"end":102},"obj":"Sentence"}],"attributes":[{"subj":"T28","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93ecd5","default":true},{"id":"CORD-19_Custom_license_subset","color":"#ecbb93"}]}]}}